Evidence map›Paper›PMID 41616264›Full record

ArticleAntimicrobial agents and chemotherapy2026

Phosphate sensitivity of KPC-2: a hidden variable in β-lactamase kinetics.

Dignite F Ngango, André Birgy, Timothy Palzkill

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dignite F NgangoVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0009-0001-3455-3338
André BirgyVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0001-9462-0582
Timothy PalzkillVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-5267-0001

Funding

NIH HHS AI32956
6 · The paper itself

Abstract

The catalytic activity of β-lactamases, particularly class A enzymes like KPC-2, is central to β-lactam antibiotic resistance. While phosphate buffers are widely used in enzymatic assays due to their physiological relevance, their potential to interfere with enzyme function remains underappreciated. Here, we demonstrate that phosphate acts as a competitive inhibitor of KPC-2 β-lactamase, significantly reducing catalytic efficiency in a concentration-dependent manner. This inhibition is mediated through interactions with threonine 237, as substitution with glycine (T237G) abolishes the inhibitory effect. In contrast, CTX-M-14 and TEM-1, which possess serine and alanine at the same position, respectively, exhibit minimal phosphate sensitivity, underscoring enzyme-specific buffer effects. Structural and kinetic analyses indicate that phosphate binding at the active site primarily impairs substrate affinity and, in some cases, also reduces catalytic turnover. These findings highlight the potential impact of buffer selection in β-lactamase assays and suggest that phosphate-mediated inhibition may lead to underestimation of enzyme activity and inhibitor potency, particularly in studies involving KPC-2. Standardizing assay conditions is essential for accurate evaluation of β-lactamase function and resistance mechanisms.

Indexed as

beta-LactamasesPhosphatesAnti-Bacterial Agentsbeta-Lactamase InhibitorsCatalytic DomainEscherichia coliKineticsAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-lactamase KPC-2beta-Lactamasesbeta-lactamase TEM-1Phosphatesantibiotic resistancebeta-lactam antibioticsbeta-lactamaseenzymology

Identifiers

PMID41616264
PMCPMC12959137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.